期刊文献+

丹红化瘀口服液联合胰岛素对早期糖尿病肾病的防治作用(英文) 被引量:9

Effect of Danhong Huayu Koufuye combined with insulin on prevention and progression of early diabetic nephropathy in rats
下载PDF
导出
摘要 丹红化瘀口服液是传统中药复方,具活血化瘀、行气通络的功效。观察丹红化瘀口服液、胰岛素及两者联合用药对糖尿病肾病大鼠的治疗效果。采用链脲佐菌素(STZ)诱导糖尿病肾病大鼠模型,STZ注射后1周后将造模成功的大鼠随机分为4组:糖尿病模型组、胰岛素组、丹红化瘀口服液组,丹红化瘀口服液联合胰岛素组,另设一正常组,每天给药1次,连续15周。丹红化瘀口服液联合胰岛素用药比两者单独用药能更显著降低空腹血糖、24 h饮水量、摄食量和尿量,降低血清尿素与尿素/肌酐比,改善肾脏肥大和肾组织病理损伤,同时提高血清Na+与Cl-水平。结果提示:丹红化瘀口服液可辅助胰岛素治疗糖尿病肾病。 Danhong Huayu Koufuye (DHK), a traditional Chinese prescription, has activities of promoting blood circulation to remove blood stasis and promoting qi circulation to remove meridian obstruction. The aim of the study was to investigate effects of DHK, insulin and their combination on diabetic nephropathy (DN) in streptozo- tocin (STZ, 50 mg/kg, ip)-induced diabetic Sprague-Dawley rats. Rats were divided into five groups: normal control, model control, insulin, DHK, and DHK plus insulin. The animals were treated once daily for 15 weeks starting one week after STZ injection. The combination of DHK with insulin resulted in more significant effects than insulin or DHK alone on decreasing fasting blood glucose, 24 h water intake, diet intake and urine volume, reducing serum urea level and urea-to-Cr ratio, promoting kidney hypertrophy and renal damage, and increasing serum Na + and Cl- level as well. These results suggest that DHK may be a valuable adjuvant therapy for DN.
出处 《中国药科大学学报》 CAS CSCD 北大核心 2013年第6期568-572,共5页 Journal of China Pharmaceutical University
基金 国家自然科学基金资助项目(No.81303282) 广州市珠江科技新星专项资助项目(No.2013J2200034) 广州中医药大学青年英才培养资助项目
关键词 丹红化瘀口服液 糖尿病肾病 链脲佐菌素 糖尿病 胰岛素抵抗 Danhong Huayu Koufuye diabetic nephropathy streptozotocin diabetic mellitus insulin resistance
  • 相关文献

参考文献2

二级参考文献93

  • 1Randers E;Kristensen JH;Erlandsen EJ.Serum cystatin C as a marker of the renal function,1998.
  • 2Go AS,Chertow GM,Fan DJ,et al.Chronic kidney disease and the risks of death, cardiovascular events, and hospitalizationNew England Journal of Medicine The,2004.
  • 3Hill JM,Zalos G,Halcox JP,et al.Circulating endothelial progenitor cells, vascular function, and cardiovascular riskNew England Journal of Medicine The,2003.
  • 4Knowler WC;Barrett-Connor E;Fowler SE.Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin,2002(06).
  • 5Coll E;Botey A.Serum Cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment,2000(01).
  • 6Filler G,Bokenkamp A,Hofmann W,et al.Cystatin C as a marker of GFR-history, indications, and future researchClinical Biochemistry,2005.
  • 7Riser BL,Denichilo M,Cortes P,et al.Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis. Journal of the American Society of Nephrology . 2000
  • 8Brenner BM,Cooper ME,Zeeuw DD,et al.Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. New England Journal of Homeopathy . 2001
  • 9Tuomilehto J,Lindstr-m J,Eriksson JG,Valle TT,H-m- -l-inen H,Ilanne-Parikka P,Kein-nen-Kiukaanniemi S,Laakso M,Louheranta A,Rastas M,Salminen V,Uusitupa M.Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. The New England Journal of Medicine . 2001
  • 10King H,Aubert RE,Herman WH.Global burden of diabetes 1995~2025: prevalence, numerical estimates and projections. Diabetes Care . 1998

共引文献24

同被引文献97

引证文献9

二级引证文献41

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部